<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702660</url>
  </required_header>
  <id_info>
    <org_study_id>GA-7</org_study_id>
    <nct_id>NCT03702660</nct_id>
  </id_info>
  <brief_title>Effect of GIP After a Meal in Patients With Type 2 Diabetes</brief_title>
  <acronym>GA-7</acronym>
  <official_title>Effect of GIP-receptorantantagonist on Glucagon Plasma Levels After a Meal in Patients With Type 2-diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of antagonising GIP after a meal on
      plasma levels of glucagon. 10 participants are going through four experimental days each,
      where they ingest a meal and afterwards receive infusions of either GIP receptor antagonist,
      GLP-1, GIP receptor antagonist + GLP-1 or placebo (saline) in a randomised order. The primary
      endpoint of the study is plasma levels of glucagon, which we hypothesize will decrease with
      infusion of GIP receptor antagonist and/or with infusion of GLP-1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">January 23, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon</measure>
    <time_frame>8 weeks - 6 months</time_frame>
    <description>Plasma levels of glucagon after a meal in patients with type 2-diabetes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>GIP(3-30)NH2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GIP receptor antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline infusions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP(3-30)NH2</intervention_name>
    <description>Peptide derived from the naturally occuring gut hormone GIP</description>
    <arm_group_label>GIP(3-30)NH2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral venous cannulation</intervention_name>
    <description>Intravenous access for infusions</description>
    <arm_group_label>GIP(3-30)NH2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians between 18-75 years with diet og Metformin treated type 2-diabetes

          -  HbA1c &lt; 75 mmol/mol

          -  BMI &gt; 27 kg/m2

          -  Stable weight (+/- 5%) during the last 3 months

        Exclusion Criteria:

          -  Treatment with medicine or dietary supplements that cannot the paused for 12 hours

          -  More than 14 units of alcohol weekly or abuse of drugs

          -  Liver disease, estimated at plasma ALAT levels &gt; 3 x normal value or INR outside
             normal range

          -  Reduced kidney function (estimated at eGFR &lt; 60 ml/min/1,73 m2)

          -  Severe arteriosclerotic heart disease or heart failure (NYHA III or IV)

          -  Low red blood cell count (hemoglobin &lt; 8.3 mmol/l

          -  Special diet or planned weight change during the trial period

          -  Any disease/condition, which the clinical investigators assess will disturb the
             participation in the clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Signe Stensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Diabetes Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Diabetes Research, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Signe Stensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

